Related references
Note: Only part of the references are listed.First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M1-receptor partial agonist for the treatment of dementias
Charlotte Bakker et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Forebrain Cholinergic Signaling: Wired and Phasic, Not Tonic, and Causing Behavior
Martin Sarter et al.
JOURNAL OF NEUROSCIENCE (2020)
Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders
Daniel Erskine et al.
DRUG DISCOVERY TODAY (2019)
Meta-analyses of the n-back working memory task: fMRI evidence of age-related changes in prefrontal cortex involvement across the adult lifespan
Zachary A. Yaple et al.
NEUROIMAGE (2019)
Reversal of mecamylamine-induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses
Ricardo Alvarez-Jimenez et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Activation of Muscarinic M1 Acetylcholine Receptors Induces Long-Term Potentiation in the Hippocampus
Siobhan H. Dennis et al.
CEREBRAL CORTEX (2016)
Muscarinic acetylcholine receptors act in synergy to facilitate learning and memory
Katherine Leaderbrand et al.
LEARNING & MEMORY (2016)
A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence
Jacob S. Buckley et al.
DRUGS & AGING (2015)
A review on Alzheimer's disease pathophysiology and its management: an update
Anil Kumar et al.
PHARMACOLOGICAL REPORTS (2015)
The M1 Muscarinic Positive Allosteric Modulator PQCA Improves Performance on Translatable Tests of Memory and Attention in Rhesus Monkeys
Henry S. Lange et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis
Chen-Chen Tan et al.
JOURNAL OF ALZHEIMERS DISEASE (2014)
Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer's disease patients
Claudio Babiloni et al.
CLINICAL NEUROPHYSIOLOGY (2013)
The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction
Pradeep J. Nathan et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2013)
被撤回的出版物: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (Retracted article. See vol. 135, pg. 2149, 2021)
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease
Pamela E. Potter et al.
ACTA NEUROPATHOLOGICA (2011)
Pharmacological Characterization of LY593093, an M1 Muscarinic Acetylcholine Receptor-Selective Partial Orthosteric Agonist
Marla L. Watt et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Lesion Evidence That Two Distinct Regions within Prefrontal Cortex are Critical for n-Back Performance in Humans
Ami Tsuchida et al.
JOURNAL OF COGNITIVE NEUROSCIENCE (2009)
M1 receptors play a central role in modulating AD-like pathology in transgenic mice
A Caccamo et al.
NEURON (2006)
Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain
M Ingelsson et al.
NEUROLOGY (2004)
Alzheimer disease: Current concepts and emerging diagnostic and therapeutic strategies
CM Clark et al.
ANNALS OF INTERNAL MEDICINE (2003)
Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease
SARB Rombouts et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2002)
Altered cardiovascular responses in mice lacking the M1 muscarinic acetylcholine receptor
SN Hardouin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Share Paper
